Rhythm’s Shares Surge After Promising Phase II Obesity Drug Results

Rhythm Pharmaceuticals saw its stock jump 36.6% after its oral obesity drug bivamelagon showed strong Phase II results in acquired hypothalamic obesity. The study showed BMI reductions of 9.3% (600mg), 7.7% (400mg), and 2.7% (200mg) after 14 weeks, while placebo patients had a 2.2% BMI increase.

Bivamelagon, an MC4R agonist, also significantly reduced hunger scores, with high and medium doses outperforming placebo. The treatment was safe and well tolerated.

The company plans to advance to Phase III trials and will consult with the FDA and EMA on trial design. Results are comparable to Rhythm’s Imcivree in similar populations.

CEO Dr. David Meeker noted the absence of a placebo effect and confidence in dosing strategy.

Rhythm in-licensed bivamelagon from LG Chem in January 2024, with total potential payments of $265 million.

10-07-2025